<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01085045</url>
  </required_header>
  <id_info>
    <org_study_id>PT0031002</org_study_id>
    <nct_id>NCT01085045</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A Randomized, Double-Blind (Test Products and Placebo), Chronic Dosing (7 Days), Four-Period, Eight-Treatment, Placebo-Controlled, Incomplete Block, Cross-Over, Multi-Center Study to Assess Efficacy and Safety of Two Doses of PT003, Two Doses of PT005 and One Dose of PT001 in Patients With Moderate to Very Severe COPD, Compared With Foradil® Aerolizer® (12 μg, Open-Label) and Spiriva® Handihaler® (18 μg, Open-Label) as Active Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pearl Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pearl Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate, after 1 week of dosing, the efficacy and safety of
      PT003 compared with its individual components (PT001 and PT005), placebo and two active
      comparators to demonstrate superiority of the combination to its components, and to assess
      the relative contribution of the components compared with placebo, in patients with moderate
      to very severe COPD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1 AUC 0-12 on Day 7</measure>
    <time_frame>&quot;Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 10, 11.5, and 12 hours post-dose on Day 7</time_frame>
    <description>Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) 0-12 (normalized) relative to baseline FEV1 following 7-day dose administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Change From BL in FEV1 on Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Peak change from Baseline in FEV1 on Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Change From BL in FEV1 on Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Peak change from Baseline (BL) in FEV1 on Day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Change From BL in Inspiratory Capacity on Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Peak change from Baseline in Inspiratory Capacity (IC) on Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Change From BL IC on Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Peak Change from Baseline Inspiratory Capacity on following 7-day dose administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Action &gt;=10% Improvement in FEV1 on Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Time to Onset of Action where the improvement in FEV1 on Day 1 was &gt;=10%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving &gt;=12% Improvement in FEV1 on Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Time to Onset of Action where the improvement in FEV1 on Day 1 was &gt;= 12%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Morning Pre-dose FEV1 on Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Change from Baseline in morning pre-dose FEV1 on Day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12 hr Post-dose Trough FEV1 on Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>12 hour post-dose trough Forced Expiratory Volume in 1 second on Day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From BL in Mean Morning Pre-dose Daily Peak Flow Rate on Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Change from BaseLine in mean morning pre-dose daily peak flow rate on Day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From BL in Mean Morning Post-dose Daily Peak Flow Rate on Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Change from BaseLine in mean morning post-dose daily peak flow rate on Day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From BL in Mean Evening Pre-dose Daily Peak Flow Rate on Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Change from BaseLine in mean evening pre-dose daily peak flow rate on Day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From BL in Mean Evening Post-dose Daily Peak Flow Rate on Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Change from BaseLine in mean evening post-dose daily peak flow rate on Day 7</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Inhaled PT003 (Dose 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT003 MDI Dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled PT003 (Dose 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT003 MDI Dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled PT005 (Dose 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT005 MDI Dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled PT005 (Dose 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT005 MDI Dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo MDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium bromide 18 μg (Spiriva Handihaler®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tiotropium Bromide inhalation powder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formoterol Fumarate 12 μg (Foradil® Aerolizer®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Formoterol fumarate inhalation powder 12 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled PT001 (Dose 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT001 MDI Dose 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT003 MDI</intervention_name>
    <description>Inhaled PT003 MDI administered as two puffs BID for 7 days</description>
    <arm_group_label>Inhaled PT003 (Dose 1)</arm_group_label>
    <arm_group_label>Inhaled PT003 (Dose 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT005 MDI</intervention_name>
    <description>Inhaled PT005 MDI administered as two puffs BID for 7 days</description>
    <arm_group_label>Inhaled PT005 (Dose 1)</arm_group_label>
    <arm_group_label>Inhaled PT005 (Dose 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo MDI</intervention_name>
    <description>Inhaled placebo administered as two puffs BID for 7 days</description>
    <arm_group_label>Inhaled Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium bromide 18 μg (Spiriva Handihaler®)</intervention_name>
    <description>Inhaled tiotropium bromide 18 μg (Spiriva Handihaler®) administered QD for 7 days</description>
    <arm_group_label>Tiotropium bromide 18 μg (Spiriva Handihaler®)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol Fumarate 12 μg (Foradil® Aerolizer®)</intervention_name>
    <description>Inhaled formoterol fumarate 12 μg (Foradil® Aerolizer®) administered BID for 7 days</description>
    <arm_group_label>Formoterol Fumarate 12 μg (Foradil® Aerolizer®)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT001 MDI</intervention_name>
    <description>Inhaled PT001 MDI administered as two puffs BID for 7 days</description>
    <arm_group_label>Inhaled PT001 (Dose 1)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent

          -  40 - 80 years of age

          -  Clinical history of COPD with airflow limitation that is not fully reversible

          -  Females of non-child bearing potential or females of child bearing potential with
             negative pregnancy test; and acceptable contraceptive methods

          -  Current/former smokers with at least a 10 pack-year history of cigarette smoking

          -  A measured post- bronchodilator FEV1/FVC ratio of &lt; or = 0.70

          -  A measured post- bronchodilator FEV1 &gt; or = 750ml or 30% predicted and &lt; or = 80% of
             predicted normal values

          -  Able to change COPD treatment as required by protocol

        Exclusion Criteria:

          -  Women who are pregnant or lactating

          -  Primary diagnosis of asthma

          -  Alpha-1 antitrypsin deficiency as the cause of COPD

          -  Active pulmonary diseases

          -  Prior lung volume reduction surgery

          -  Abnormal chest X-ray (or CT scan) not due to the presence of COPD

          -  Hospitalized due to poorly controlled COPD within 3 months of Screening

          -  Clinically significant medical conditions that preclude participation in the study
             (e.g. clinically significant abnormal ECG, uncontrolled hypertension, glaucoma,
             symptomatic prostatic hypertrophy)

          -  Cancer that has not been in complete remission for at least 5 years

          -  Treatment with investigational study drug or participation in another clinical trial
             or study within the last 30 days or 5 half lives

        Other protocol defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colin Reisner, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Pearl Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research of West Florida, Inc.</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Health Research</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute of Southern Oregon, PC</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spartanburg Medical Research</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austrials</name>
      <address>
        <city>Caringbah</city>
        <state>New South Wales</state>
        <zip>2229</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woolcock</name>
      <address>
        <city>Glebe</city>
        <state>New South Wales</state>
        <zip>2037</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austrials</name>
      <address>
        <city>Hornsby</city>
        <state>New South Wales</state>
        <zip>2077</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austrials</name>
      <address>
        <city>Auchenflower</city>
        <state>Queensland</state>
        <zip>4066</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Q-Pharm</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Respiratory Research Foundation - Burnside War Memorial Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lung Institute of WA</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenlane Clinical Centre</name>
      <address>
        <city>Epsom</city>
        <state>Auckland</state>
        <zip>1051</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZ Respiratory &amp; Sleep Institute</name>
      <address>
        <city>Greenlane East</city>
        <state>Auckland</state>
        <zip>1051</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Waikato</state>
        <zip>3240</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P3 Research</name>
      <address>
        <city>Crofton Downs</city>
        <state>Wellington</state>
        <zip>6143</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2010</study_first_submitted>
  <study_first_submitted_qc>March 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2010</study_first_posted>
  <results_first_submitted>May 24, 2016</results_first_submitted>
  <results_first_submitted_qc>March 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 26, 2017</results_first_posted>
  <disposition_first_submitted>September 11, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>September 11, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 13, 2012</disposition_first_posted>
  <last_update_submitted>March 14, 2017</last_update_submitted>
  <last_update_submitted_qc>March 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Conducted at 16 sites in Australia, New Zealand and the US from 24 March 2010 -28 October 2010. The entire study period was a maximum of 20 weeks. Chronic dosing (7 days), 4-period, 8-treatment, incomplete block, cross-over conducted in two parts.</recruitment_details>
      <pre_assignment_details>Part A: 4-period, 8-treatment, incomplete block cross-over. Subjects randomized to 1 of 48 sequences, each subject received 4 of 8 possible treatments. Part B: 4-period, 4-treatment, full cross-over. Each subject randomized to 1 of 24 sequences and each sequence was assigned to at least 1 subject.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Overall Study</title>
          <description>Sentinel patients were the first 4 patients enrolled to receive one week of treatment with either GFF MDI 72/9.6mcg, GFF MDI 36/9.6 mcg, GP MDI 36 mcg or FF MDI 9.6 mcg because this was the first time GFF MDI was administered to patients with COPD, the sentinel patients provided additional assurance of safety.9.6</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part A</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>GFF MDI 72/9.6mcg</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>GFF MDI 36/9.6 µg (PT003)</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>GP MDI 36 µg (PT001)</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Spiriva 18 µg</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>FF MDI 9.6 µg (PT005)</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>FF MDI 7.2 µg (PT005)</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Placebo MDI</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Foradil 12 µg</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Specified Criteria</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part B</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>GFF MDI 72/9.6mcg (PT003)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>GFF MDI 36/9.6 µg</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Spiriva 18 µg</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>FF MDI 9.6 µg (PT005)</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>FF MDI 7.2 µg (PT005)</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Placebo MDI</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Foradil 12 µg</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>GP MDI 36 µg (PT001)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Specified Criteria</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis Population included all randomized participants. 118 plus 4 sentinel patients to make 122.</population>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>All Baseline Subjects</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="122"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.4" spread="8.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>FEV1 AUC 0-12 on Day 7</title>
        <description>Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) 0-12 (normalized) relative to baseline FEV1 following 7-day dose administration</description>
        <time_frame>&quot;Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 10, 11.5, and 12 hours post-dose on Day 7</time_frame>
        <population>Modified Intent to Treat (MITT) Population - not including the 4 sentinel patients.</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 72/9.6 μg</title>
            <description>GFF MDI 72/9.6 μg (PT003)</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI 36/9.6 μg</title>
            <description>GFF MDI 36/9.6 μg (PT003)</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 36 μg</title>
            <description>GP MDI 36 μg (PT001)</description>
          </group>
          <group group_id="O4">
            <title>Spiriva 18 μg</title>
            <description>Spiriva 18 μg</description>
          </group>
          <group group_id="O5">
            <title>FF MDI 9.6 μg</title>
            <description>FF MDI 9.6 μg (PT005)</description>
          </group>
          <group group_id="O6">
            <title>FF MDI 7.2 μg</title>
            <description>FF MDI 7.2 μg (PT005)</description>
          </group>
          <group group_id="O7">
            <title>Foradil 12 μg</title>
            <description>Foradil 12 μg</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC 0-12 on Day 7</title>
          <description>Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) 0-12 (normalized) relative to baseline FEV1 following 7-day dose administration</description>
          <population>Modified Intent to Treat (MITT) Population - not including the 4 sentinel patients.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="58"/>
                <count group_id="O7" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.537" lower_limit="1.499" upper_limit="1.575"/>
                    <measurement group_id="O2" value="1.529" lower_limit="1.492" upper_limit="1.567"/>
                    <measurement group_id="O3" value="1.429" lower_limit="1.389" upper_limit="1.469"/>
                    <measurement group_id="O4" value="1.434" lower_limit="1.401" upper_limit="1.467"/>
                    <measurement group_id="O5" value="1.421" lower_limit="1.386" upper_limit="1.455"/>
                    <measurement group_id="O6" value="1.413" lower_limit="1.379" upper_limit="1.446"/>
                    <measurement group_id="O7" value="1.437" lower_limit="1.401" upper_limit="1.472"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From BL in FEV1 on Day 1</title>
        <description>Peak change from Baseline in FEV1 on Day 1</description>
        <time_frame>Day 1</time_frame>
        <population>MITT Population - not including the 4 sentinel patients.</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 72/9.6 μg</title>
            <description>GFF MDI 72/9.6 μg (PT003)</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI 36/9.6 μg</title>
            <description>GFF MDI 36/9.6 μg (PT003)</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 36 μg</title>
            <description>GP MDI 36 μg (PT001)</description>
          </group>
          <group group_id="O4">
            <title>Spiriva 18 μg</title>
            <description>Spiriva 18 μg</description>
          </group>
          <group group_id="O5">
            <title>FF MDI 9.6 μg</title>
            <description>FF MDI 9.6 μg (PT005)</description>
          </group>
          <group group_id="O6">
            <title>FF MDI 7.2 μg</title>
            <description>FF MDI 7.2 μg (PT005)</description>
          </group>
          <group group_id="O7">
            <title>Foradil 12 μg</title>
            <description>Foradil 12 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From BL in FEV1 on Day 1</title>
          <description>Peak change from Baseline in FEV1 on Day 1</description>
          <population>MITT Population - not including the 4 sentinel patients.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="56"/>
                <count group_id="O5" value="58"/>
                <count group_id="O6" value="63"/>
                <count group_id="O7" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.370" lower_limit="0.325" upper_limit="0.416"/>
                    <measurement group_id="O2" value="0.357" lower_limit="0.312" upper_limit="0.401"/>
                    <measurement group_id="O3" value="0.289" lower_limit="0.243" upper_limit="0.335"/>
                    <measurement group_id="O4" value="0.266" lower_limit="0.229" upper_limit="0.304"/>
                    <measurement group_id="O5" value="0.308" lower_limit="0.269" upper_limit="0.348"/>
                    <measurement group_id="O6" value="0.310" lower_limit="0.273" upper_limit="0.348"/>
                    <measurement group_id="O7" value="0.299" lower_limit="0.258" upper_limit="0.340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From BL in FEV1 on Day 7</title>
        <description>Peak change from Baseline (BL) in FEV1 on Day 7</description>
        <time_frame>Day 7</time_frame>
        <population>MITT Population - not including the 4 sentinel patients.</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 72/9.6 μg</title>
            <description>GFF MDI 72/9.6 μg (PT003)</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI 36/9.6 μg</title>
            <description>GFF MDI 36/9.6 μg (PT003)</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 36 μg</title>
            <description>GP MDI 36 μg (PT001)</description>
          </group>
          <group group_id="O4">
            <title>Spiriva 18 μg</title>
            <description>Spiriva 18 μg</description>
          </group>
          <group group_id="O5">
            <title>FF MDI 9.6 μg</title>
            <description>FF MDI 9.6 μg (PT005)</description>
          </group>
          <group group_id="O6">
            <title>FF MDI 7.2 μg</title>
            <description>FF MDI 7.2 μg (PT005)</description>
          </group>
          <group group_id="O7">
            <title>Foradil 12 μg</title>
            <description>Foradil 12 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From BL in FEV1 on Day 7</title>
          <description>Peak change from Baseline (BL) in FEV1 on Day 7</description>
          <population>MITT Population - not including the 4 sentinel patients.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="58"/>
                <count group_id="O6" value="61"/>
                <count group_id="O7" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.438" lower_limit="0.396" upper_limit="0.481"/>
                    <measurement group_id="O2" value="0.440" lower_limit="0.398" upper_limit="0.481"/>
                    <measurement group_id="O3" value="0.313" lower_limit="0.270" upper_limit="0.356"/>
                    <measurement group_id="O4" value="0.298" lower_limit="0.262" upper_limit="0.335"/>
                    <measurement group_id="O5" value="0.337" lower_limit="0.300" upper_limit="0.374"/>
                    <measurement group_id="O6" value="0.330" lower_limit="0.294" upper_limit="0.366"/>
                    <measurement group_id="O7" value="0.356" lower_limit="0.317" upper_limit="0.395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From BL in Inspiratory Capacity on Day 1</title>
        <description>Peak change from Baseline in Inspiratory Capacity (IC) on Day 1</description>
        <time_frame>Day 1</time_frame>
        <population>MITT Population - not including the 4 sentinel patients.</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 72/9.6 μg</title>
            <description>GFF MDI 72/9.6 μg (PT003)</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI 36/9.6 μg</title>
            <description>GFF MDI 36/9.6 μg (PT003)</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 36 μg</title>
            <description>GP MDI 36 μg (PT001)</description>
          </group>
          <group group_id="O4">
            <title>Spiriva 18 μg</title>
            <description>Spiriva 18 μg</description>
          </group>
          <group group_id="O5">
            <title>FF MDI 9.6 μg</title>
            <description>FF MDI 9.6 μg (PT005)</description>
          </group>
          <group group_id="O6">
            <title>FF MDI 7.2 μg</title>
            <description>FF MDI 7.2 μg (PT005)</description>
          </group>
          <group group_id="O7">
            <title>Foradil 12 μg</title>
            <description>Foradil 12 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From BL in Inspiratory Capacity on Day 1</title>
          <description>Peak change from Baseline in Inspiratory Capacity (IC) on Day 1</description>
          <population>MITT Population - not including the 4 sentinel patients.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="56"/>
                <count group_id="O5" value="58"/>
                <count group_id="O6" value="63"/>
                <count group_id="O7" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.495" lower_limit="0.411" upper_limit="0.579"/>
                    <measurement group_id="O2" value="0.411" lower_limit="0.330" upper_limit="0.493"/>
                    <measurement group_id="O3" value="0.430" lower_limit="0.346" upper_limit="0.514"/>
                    <measurement group_id="O4" value="0.347" lower_limit="0.278" upper_limit="0.416"/>
                    <measurement group_id="O5" value="0.362" lower_limit="0.290" upper_limit="0.433"/>
                    <measurement group_id="O6" value="0.352" lower_limit="0.283" upper_limit="0.420"/>
                    <measurement group_id="O7" value="0.374" lower_limit="0.299" upper_limit="0.449"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From BL IC on Day 7</title>
        <description>Peak Change from Baseline Inspiratory Capacity on following 7-day dose administration</description>
        <time_frame>Day 7</time_frame>
        <population>MITT Population - not including the 4 sentinel patients.</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 72/9.6 μg</title>
            <description>GFF MDI 72/9.6 μg (PT003)</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI 36/9.6 μg</title>
            <description>GFF MDI 36/9.6 μg (PT003)</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 36 μg</title>
            <description>GP MDI 36 μg (PT001)</description>
          </group>
          <group group_id="O4">
            <title>Spiriva 18 μg</title>
            <description>Spiriva 18 μg</description>
          </group>
          <group group_id="O5">
            <title>FF MDI 9.6 μg</title>
            <description>FF MDI 9.6 μg (PT005)</description>
          </group>
          <group group_id="O6">
            <title>FF MDI 7.2 μg</title>
            <description>FF MDI 7.2 μg (PT005)</description>
          </group>
          <group group_id="O7">
            <title>Foradil 12 μg</title>
            <description>Foradil 12 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From BL IC on Day 7</title>
          <description>Peak Change from Baseline Inspiratory Capacity on following 7-day dose administration</description>
          <population>MITT Population - not including the 4 sentinel patients.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="58"/>
                <count group_id="O6" value="61"/>
                <count group_id="O7" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.409" lower_limit="0.327" upper_limit="0.491"/>
                    <measurement group_id="O2" value="0.438" lower_limit="0.359" upper_limit="0.516"/>
                    <measurement group_id="O3" value="0.331" lower_limit="0.249" upper_limit="0.412"/>
                    <measurement group_id="O4" value="0.314" lower_limit="0.244" upper_limit="0.383"/>
                    <measurement group_id="O5" value="0.359" lower_limit="0.289" upper_limit="0.430"/>
                    <measurement group_id="O6" value="0.376" lower_limit="0.307" upper_limit="0.444"/>
                    <measurement group_id="O7" value="0.393" lower_limit="0.319" upper_limit="0.466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Action &gt;=10% Improvement in FEV1 on Day 1</title>
        <description>Time to Onset of Action where the improvement in FEV1 on Day 1 was &gt;=10%</description>
        <time_frame>Day 1</time_frame>
        <population>MITT Population - not including the 4 sentinel patients.</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 72/9.6 μg</title>
            <description>GFF MDI 72/9.6 μg (PT003)</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI 36/9.6 μg</title>
            <description>GFF MDI 36/9.6 μg (PT003)</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 36 μg</title>
            <description>GP MDI 36 μg (PT001)</description>
          </group>
          <group group_id="O4">
            <title>Spiriva 18 μg</title>
            <description>Spiriva 18 μg</description>
          </group>
          <group group_id="O5">
            <title>FF MDI 9.6 μg</title>
            <description>FF MDI 9.6 μg (PT005)</description>
          </group>
          <group group_id="O6">
            <title>FF MDI 7.2 μg</title>
            <description>FF MDI 7.2 μg (PT005)</description>
          </group>
          <group group_id="O7">
            <title>Foradil 12 μg</title>
            <description>Foradil 12 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Action &gt;=10% Improvement in FEV1 on Day 1</title>
          <description>Time to Onset of Action where the improvement in FEV1 on Day 1 was &gt;=10%</description>
          <population>MITT Population - not including the 4 sentinel patients.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="57"/>
                <count group_id="O6" value="61"/>
                <count group_id="O7" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>15 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="37"/>
                    <measurement group_id="O6" value="34"/>
                    <measurement group_id="O7" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No onset</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving &gt;=12% Improvement in FEV1 on Day 1</title>
        <description>Time to Onset of Action where the improvement in FEV1 on Day 1 was &gt;= 12%</description>
        <time_frame>Day 1</time_frame>
        <population>MITT Population - not including the 4 sentinel patients.</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 72/9.6 μg</title>
            <description>GFF MDI 72/9.6 μg (PT003)</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI 36/9.6 μg</title>
            <description>GFF MDI 36/9.6 μg (PT003)</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 36 μg</title>
            <description>GP MDI 36 μg (PT001)</description>
          </group>
          <group group_id="O4">
            <title>Spiriva 18 μg</title>
            <description>Spiriva 18 μg</description>
          </group>
          <group group_id="O5">
            <title>FF MDI 9.6 μg</title>
            <description>FF MDI 9.6 μg (PT005)</description>
          </group>
          <group group_id="O6">
            <title>FF MDI 7.2 μg</title>
            <description>FF MDI 7.2 μg (PT005)</description>
          </group>
          <group group_id="O7">
            <title>Foradil 12 μg</title>
            <description>Foradil 12 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving &gt;=12% Improvement in FEV1 on Day 1</title>
          <description>Time to Onset of Action where the improvement in FEV1 on Day 1 was &gt;= 12%</description>
          <population>MITT Population - not including the 4 sentinel patients.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="56"/>
                <count group_id="O5" value="58"/>
                <count group_id="O6" value="63"/>
                <count group_id="O7" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.84"/>
                    <measurement group_id="O2" value="87.18"/>
                    <measurement group_id="O3" value="73.68"/>
                    <measurement group_id="O4" value="66.07"/>
                    <measurement group_id="O5" value="84.48"/>
                    <measurement group_id="O6" value="82.54"/>
                    <measurement group_id="O7" value="85.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Morning Pre-dose FEV1 on Day 7</title>
        <description>Change from Baseline in morning pre-dose FEV1 on Day 7</description>
        <time_frame>Day 7</time_frame>
        <population>MITT Population - not including the 4 sentinel patients.</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 72/9.6 μg</title>
            <description>GFF MDI 72/9.6 μg (PT003)</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI 36/9.6 μg</title>
            <description>GFF MDI 36/9.6 μg (PT003)</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 36 μg</title>
            <description>GP MDI 36 μg (PT001)</description>
          </group>
          <group group_id="O4">
            <title>Spiriva 18 μg</title>
            <description>Spiriva 18 μg</description>
          </group>
          <group group_id="O5">
            <title>FF MDI 9.6 μg</title>
            <description>FF MDI 9.6 μg (PT005)</description>
          </group>
          <group group_id="O6">
            <title>FF MDI 7.2 μg</title>
            <description>FF MDI 7.2 μg (PT005)</description>
          </group>
          <group group_id="O7">
            <title>Foradil 12 μg</title>
            <description>Foradil 12 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Morning Pre-dose FEV1 on Day 7</title>
          <description>Change from Baseline in morning pre-dose FEV1 on Day 7</description>
          <population>MITT Population - not including the 4 sentinel patients.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="58"/>
                <count group_id="O6" value="61"/>
                <count group_id="O7" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.193" lower_limit="0.148" upper_limit="0.237"/>
                    <measurement group_id="O2" value="0.170" lower_limit="0.126" upper_limit="0.213"/>
                    <measurement group_id="O3" value="0.097" lower_limit="0.052" upper_limit="0.142"/>
                    <measurement group_id="O4" value="0.097" lower_limit="0.058" upper_limit="0.136"/>
                    <measurement group_id="O5" value="0.064" lower_limit="0.024" upper_limit="0.103"/>
                    <measurement group_id="O6" value="0.073" lower_limit="0.034" upper_limit="0.111"/>
                    <measurement group_id="O7" value="0.101" lower_limit="0.060" upper_limit="0.142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>12 hr Post-dose Trough FEV1 on Day 7</title>
        <description>12 hour post-dose trough Forced Expiratory Volume in 1 second on Day 7</description>
        <time_frame>Day 7</time_frame>
        <population>MITT Population - not including the 4 sentinel patients.</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 72/9.6 μg</title>
            <description>GFF MDI 72/9.6 μg (PT003)</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI 36/9.6 μg</title>
            <description>GFF MDI 36/9.6 μg (PT003)</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 36 μg</title>
            <description>GP MDI 36 μg (PT001)</description>
          </group>
          <group group_id="O4">
            <title>Spiriva 18 μg</title>
            <description>Spiriva 18 μg</description>
          </group>
          <group group_id="O5">
            <title>FF MDI 9.6 μg</title>
            <description>FF MDI 9.6 μg (PT005)</description>
          </group>
          <group group_id="O6">
            <title>FF MDI 7.2 μg</title>
            <description>FF MDI 7.2 μg (PT005)</description>
          </group>
          <group group_id="O7">
            <title>Foradil 12 μg</title>
            <description>Foradil 12 μg</description>
          </group>
        </group_list>
        <measure>
          <title>12 hr Post-dose Trough FEV1 on Day 7</title>
          <description>12 hour post-dose trough Forced Expiratory Volume in 1 second on Day 7</description>
          <population>MITT Population - not including the 4 sentinel patients.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="58"/>
                <count group_id="O7" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.405" lower_limit="1.358" upper_limit="1.453"/>
                    <measurement group_id="O2" value="1.441" lower_limit="1.395" upper_limit="1.488"/>
                    <measurement group_id="O3" value="1.383" lower_limit="1.333" upper_limit="1.432"/>
                    <measurement group_id="O4" value="1.398" lower_limit="1.357" upper_limit="1.439"/>
                    <measurement group_id="O5" value="1.349" lower_limit="1.306" upper_limit="1.393"/>
                    <measurement group_id="O6" value="1.378" lower_limit="1.336" upper_limit="1.419"/>
                    <measurement group_id="O7" value="1.358" lower_limit="1.314" upper_limit="1.402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From BL in Mean Morning Pre-dose Daily Peak Flow Rate on Day 7</title>
        <description>Change from BaseLine in mean morning pre-dose daily peak flow rate on Day 7</description>
        <time_frame>Day 7</time_frame>
        <population>MITT Population - not including the 4 sentinel patients.</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 72/9.6 μg</title>
            <description>GFF MDI 72/9.6 μg (PT003)</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI 36/9.6 μg</title>
            <description>GFF MDI 36/9.6 μg (PT003)</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 36 μg</title>
            <description>GP MDI 36 μg (PT001)</description>
          </group>
          <group group_id="O4">
            <title>Spiriva 18 μg</title>
            <description>Spiriva 18 μg</description>
          </group>
          <group group_id="O5">
            <title>FF MDI 9.6 μg</title>
            <description>FF MDI 9.6 μg (PT005)</description>
          </group>
          <group group_id="O6">
            <title>FF MDI 7.2 μg</title>
            <description>FF MDI 7.2 μg (PT005)</description>
          </group>
          <group group_id="O7">
            <title>Foradil 12 μg</title>
            <description>Foradil 12 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From BL in Mean Morning Pre-dose Daily Peak Flow Rate on Day 7</title>
          <description>Change from BaseLine in mean morning pre-dose daily peak flow rate on Day 7</description>
          <population>MITT Population - not including the 4 sentinel patients.</population>
          <units>Liters / Minute</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="60"/>
                <count group_id="O7" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.263" lower_limit="21.479" upper_limit="39.046"/>
                    <measurement group_id="O2" value="28.152" lower_limit="19.756" upper_limit="36.547"/>
                    <measurement group_id="O3" value="16.439" lower_limit="7.620" upper_limit="25.259"/>
                    <measurement group_id="O4" value="11.817" lower_limit="4.316" upper_limit="19.317"/>
                    <measurement group_id="O5" value="12.424" lower_limit="4.593" upper_limit="20.256"/>
                    <measurement group_id="O6" value="10.211" lower_limit="2.692" upper_limit="17.730"/>
                    <measurement group_id="O7" value="13.426" lower_limit="5.426" upper_limit="21.426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From BL in Mean Morning Post-dose Daily Peak Flow Rate on Day 7</title>
        <description>Change from BaseLine in mean morning post-dose daily peak flow rate on Day 7</description>
        <time_frame>Day 7</time_frame>
        <population>MITT Population - not including the 4 sentinel patients.</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 72/9.6 μg</title>
            <description>GFF MDI 72/9.6 μg (PT003)</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI 36/9.6 μg</title>
            <description>GFF MDI 36/9.6 μg (PT003)</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 36 μg</title>
            <description>GP MDI 36 μg (PT001)</description>
          </group>
          <group group_id="O4">
            <title>Spiriva 18 μg</title>
            <description>Spiriva 18 μg</description>
          </group>
          <group group_id="O5">
            <title>FF MDI 9.6 μg</title>
            <description>FF MDI 9.6 μg (PT005)</description>
          </group>
          <group group_id="O6">
            <title>FF MDI 7.2 μg</title>
            <description>FF MDI 7.2 μg (PT005)</description>
          </group>
          <group group_id="O7">
            <title>Foradil 12 μg</title>
            <description>Foradil 12 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From BL in Mean Morning Post-dose Daily Peak Flow Rate on Day 7</title>
          <description>Change from BaseLine in mean morning post-dose daily peak flow rate on Day 7</description>
          <population>MITT Population - not including the 4 sentinel patients.</population>
          <units>Liters / Minute</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="60"/>
                <count group_id="O7" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.666" lower_limit="47.631" upper_limit="65.700"/>
                    <measurement group_id="O2" value="53.411" lower_limit="44.600" upper_limit="62.221"/>
                    <measurement group_id="O3" value="33.652" lower_limit="24.553" upper_limit="42.750"/>
                    <measurement group_id="O4" value="27.668" lower_limit="19.742" upper_limit="35.594"/>
                    <measurement group_id="O5" value="41.287" lower_limit="33.105" upper_limit="49.468"/>
                    <measurement group_id="O6" value="38.712" lower_limit="30.799" upper_limit="46.624"/>
                    <measurement group_id="O7" value="39.132" lower_limit="30.761" upper_limit="47.502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From BL in Mean Evening Pre-dose Daily Peak Flow Rate on Day 7</title>
        <description>Change from BaseLine in mean evening pre-dose daily peak flow rate on Day 7</description>
        <time_frame>Day 7</time_frame>
        <population>MITT Population - not including the 4 sentinel patients.</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 72/9.6 μg</title>
            <description>GFF MDI 72/9.6 μg (PT003)</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI 36/9.6 μg</title>
            <description>GFF MDI 36/9.6 μg (PT003)</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 36 μg</title>
            <description>GP MDI 36 μg (PT001)</description>
          </group>
          <group group_id="O4">
            <title>FF MDI 9.6 μg</title>
            <description>FF MDI 9.6 μg (PT005)</description>
          </group>
          <group group_id="O5">
            <title>FF MDI 7.2 μg</title>
            <description>FF MDI 7.2 μg (PT005)</description>
          </group>
          <group group_id="O6">
            <title>Foradil 12 μg</title>
            <description>Foradil 12 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From BL in Mean Evening Pre-dose Daily Peak Flow Rate on Day 7</title>
          <description>Change from BaseLine in mean evening pre-dose daily peak flow rate on Day 7</description>
          <population>MITT Population - not including the 4 sentinel patients.</population>
          <units>Liters / Minute</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="56"/>
                <count group_id="O5" value="60"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0945" lower_limit="25.888" upper_limit="44.302"/>
                    <measurement group_id="O2" value="30.817" lower_limit="21.713" upper_limit="39.920"/>
                    <measurement group_id="O3" value="18.487" lower_limit="9.034" upper_limit="27.939"/>
                    <measurement group_id="O4" value="17.190" lower_limit="9.029" upper_limit="25.350"/>
                    <measurement group_id="O5" value="14.805" lower_limit="6.800" upper_limit="22.810"/>
                    <measurement group_id="O6" value="17.789" lower_limit="9.383" upper_limit="26.194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From BL in Mean Evening Post-dose Daily Peak Flow Rate on Day 7</title>
        <description>Change from BaseLine in mean evening post-dose daily peak flow rate on Day 7</description>
        <time_frame>Day 7</time_frame>
        <population>MITT Population - not including the 4 sentinel patients.</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 72/9.6 μg</title>
            <description>GFF MDI 72/9.6 μg (PT003)</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI 36/9.6 μg</title>
            <description>GFF MDI 36/9.6 μg (PT003)</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 36 μg</title>
            <description>GP MDI 36 μg (PT001)</description>
          </group>
          <group group_id="O4">
            <title>Spiriva 18 μg</title>
            <description>Spiriva 18 μg</description>
          </group>
          <group group_id="O5">
            <title>FF MDI 9.6 μg</title>
            <description>FF MDI 9.6 μg (PT005)</description>
          </group>
          <group group_id="O6">
            <title>FF MDI 7.2 μg</title>
            <description>FF MDI 7.2 μg (PT005)</description>
          </group>
          <group group_id="O7">
            <title>Foradil 12 μg</title>
            <description>Foradil 12 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From BL in Mean Evening Post-dose Daily Peak Flow Rate on Day 7</title>
          <description>Change from BaseLine in mean evening post-dose daily peak flow rate on Day 7</description>
          <population>MITT Population - not including the 4 sentinel patients.</population>
          <units>Liters / Minute</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="59"/>
                <count group_id="O7" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.863" lower_limit="43.924" upper_limit="63.802"/>
                    <measurement group_id="O2" value="58.326" lower_limit="48.553" upper_limit="68.099"/>
                    <measurement group_id="O3" value="36.637" lower_limit="26.685" upper_limit="46.589"/>
                    <measurement group_id="O4" value="24.253" lower_limit="15.172" upper_limit="33.335"/>
                    <measurement group_id="O5" value="41.395" lower_limit="32.252" upper_limit="50.538"/>
                    <measurement group_id="O6" value="37.192" lower_limit="28.251" upper_limit="46.132"/>
                    <measurement group_id="O7" value="39.323" lower_limit="30.024" upper_limit="48.621"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the time the subject signed consent through Visit 10/Final Visit (7-14 days post final dose).</time_frame>
      <desc>Serious Adverse Events (SAE) were captured from the time subjects sign the ICF through the final visit or premature discontinuation visit up to 30 days following the last dose of study drug. Safety population included all participants who were randomized to treatment and received at least one dose of one study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>GP/FF MDI 72/9.6 μg</title>
          <description>GP/FF MDI 72/9.6 μg (PT003)</description>
        </group>
        <group group_id="E2">
          <title>GP/FF MDI 36/9.6 μg</title>
          <description>GP/FF MDI 36/9.6 μg (PT003)</description>
        </group>
        <group group_id="E3">
          <title>GP MDI 36 μg</title>
          <description>GP MDI 36 μg (PT001)</description>
        </group>
        <group group_id="E4">
          <title>Spiriva</title>
          <description>Handihaler 18 μg</description>
        </group>
        <group group_id="E5">
          <title>FF MDI 9.6 μg</title>
          <description>FF MDI 9.6 μg (PT005)</description>
        </group>
        <group group_id="E6">
          <title>FF MDI 7.2 μg</title>
          <description>FF MDI 7.2 μg (PT005)</description>
        </group>
        <group group_id="E7">
          <title>Placebo</title>
          <description>Placebo MDI</description>
        </group>
        <group group_id="E8">
          <title>Foradil Aerolizer</title>
          <description>Foradil Aerolizer 12 μg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Foreign Body Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="58"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E8" events="4" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E2" events="19" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent its opinions, or the opinions of the publication committee, if these differ with the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Colin Reisner, MD, FCCP, FAAAAI</name_or_title>
      <organization>Pearl Therapeutics, Inc</organization>
      <phone>650-305-2600</phone>
      <email>creisner@pearltherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

